Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionRed Spruce Capital, LLC
Latest Disclosed Ownership17,209 shares
Latest Disclosed Value $ 2,267,114
Red Spruce Capital, LLC reports 0.31% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On April 9, 2026 - Red Spruce Capital, LLC filed a 13F-HR form disclosing ownership of 17,209 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $2,267,114 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 6, 2026 disclosing 17,155 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 0.31% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-09 2026-03-31 13F Neurocrine Biosciences, Inc. - COM 64125C109 17,209 54 0.31 2,267 -6.82 0.9308
2026-01-06 2025-12-31 13F Neurocrine Biosciences, Inc. - COM 64125C109 17,155 -213 -1.23 2,433 -0.21 0.9699
2025-10-06 2025-09-30 13F Neurocrine Biosciences, Inc. - COM 64125C109 17,368 1,791 11.50 2,438 24.58 0.9941
2025-07-08 2025-06-30 13F Neurocrine Biosciences, Inc. - COM 64125C109 15,577 0 0.00 1,958 13.65 0.8486
2025-04-08 2025-03-31 13F Neurocrine Biosciences, Inc. - COM 64125C109 15,577 -344 -2.16 1,723 -20.75 0.8101
2025-01-17 2024-12-31 13F Neurocrine Biosciences, Inc. - COM 64125C109 15,921 15 0.09 2,173 18.61 0.9645
2024-10-04 2024-09-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 15,906 -244 -1.51 1,833 -17.59 0.8334
2024-07-02 2024-06-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 16,150 124 0.77 2,223 0.59 1.0323
2024-04-10 2024-03-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 16,026 0 0.00 2,210 4.69 1.0254
2024-01-05 2023-12-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 16,026 101 0.63 2,112 17.87 1.0841
2023-10-03 2023-09-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 15,925 0 0.00 1,792 19.32 1.0170
2023-07-05 2023-06-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 15,925 261 1.67 1,502 -5.30 0.8087
2023-04-06 2023-03-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 15,664 386 2.53 1,586 -13.10 0.9279
2023-01-03 2022-12-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 15,278 75 0.49 1,825 12.94 1.1615
2022-10-03 2022-09-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 15,203 121 0.80 1,615 9.86 1.1336
2022-07-05 2022-06-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 15,082 228 1.53 1,470 5.53 0.9799
2022-04-05 2022-03-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 14,854 1,915 14.80 1,393 26.41 0.7900
2022-01-03 2021-12-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 12,939 1,193 10.16 1,102 -2.22 0.6028
2021-10-04 2021-09-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 11,746 -105 -0.89 1,127 -2.25 0.6595
2021-07-06 2021-06-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 11,851 0 0.00 1,153 0.00 0.6803
2021-04-01 2021-03-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 11,851 285 2.46 1,153 3.97 0.7329
2021-01-04 2020-12-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 11,566 422 3.79 1,109 3.45 0.7701
2020-10-02 2020-09-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 11,144 1,235 12.46 1,072 -11.33 0.8717
2020-07-02 2020-06-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 9,909 36 0.36 1,209 41.40 1.0257
2020-04-06 2020-03-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 9,873 -53 -0.53 855 -19.87 0.8886
2020-01-16 2019-12-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 9,926 9,926 1,067 0.8896
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.